Recombinant osteoprotegerin - Amgen
Alternative Names: AMGN-0007; OCIF - Amgen; OPG - Amgen; Osteoclastogenesis Inhibiting Factor - AmgenLatest Information Update: 23 Sep 2021
At a glance
- Originator Amgen
- Class
- Mechanism of Action Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperparathyroidism
- Discontinued Bone disorders; Cancer pain; Postmenopausal osteoporosis; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hyperparathyroidism in USA
- 15 Sep 2009 Preclinical trials in Hyperparathyroidism in USA (unspecified route)
- 15 Sep 2009 Pharmacodynamics data from a preclinical trial in Hyperparathyroidism presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2009)